Syndexa is dedicated to the discovery and development of a new generation of small-molecule drugs targeting novel mechanisms for the treatment and prevention of diseases of endoplasmic reticulum (ER) dysfunction which include inflammatory and metabolic diseases and disorders, cardiovascular diseases and neurodegenerative diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/05/12 | undisclosed | Series B-1 |
MP Healthcare Venture Management | undisclosed |
